Asenapine versus placebo for schizophrenia

Area of Science:

• Psychiatry
• Clinical Pharmacology
• Evidence-Based Medicine

Background:

• Schizophrenia is a prevalent, chronic mental disorder with diverse symptoms.
• Asenapine is an atypical antipsychotic approved for schizophrenia treatment by the US FDA.

Purpose of the Study:

• To evaluate the clinical efficacy of asenapine versus placebo in adults with schizophrenia or related disorders.
• To assess the impact of asenapine on various symptom domains and adverse effects.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) comparing asenapine with placebo.
• Searched Cochrane Schizophrenia Group's Trials Register and other databases.
• Extracted data and performed meta-analysis using fixed-effect models; assessed evidence quality using GRADE.

Main Results:

• Six RCTs (n=1835) were included; five had high attrition bias, and all were industry-sponsored.
• Asenapine showed low-to-very low-quality evidence of improvement in global and mental state, and negative symptoms.
• Significantly fewer serious adverse effects were observed with asenapine (medium-term); no difference in study discontinuation rates.

Conclusions:

• Preliminary evidence suggests asenapine may improve positive, negative, and depressive symptoms while reducing adverse effects.
• The limited quantity and low quality of current evidence make definitive recommendations challenging.
• Large-scale, longer-term, well-designed RCTs are necessary to establish the clinical utility and safety of asenapine for schizophrenia.